Cargando…

Multi-omics analysis reveals attenuation of cellular stress by empagliflozin in high glucose-treated human cardiomyocytes

BACKGROUND: Sodium–glucose cotransporter 2 (SGLT2) inhibitors constitute the gold standard treatment for type 2 diabetes mellitus (T2DM). Among them, empagliflozin (EMPA) has shown beneficial effects against heart failure. Because cardiovascular diseases (mainly diabetic cardiomyopathy) are the lead...

Descripción completa

Detalles Bibliográficos
Autores principales: Scisciola, Lucia, Chianese, Ugo, Caponigro, Vicky, Basilicata, Manuela Giovanna, Salviati, Emanuela, Altucci, Lucia, Campiglia, Pietro, Paolisso, Giuseppe, Barbieri, Michelangela, Benedetti, Rosaria, Sommella, Eduardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518098/
https://www.ncbi.nlm.nih.gov/pubmed/37742032
http://dx.doi.org/10.1186/s12967-023-04537-1
_version_ 1785109439114641408
author Scisciola, Lucia
Chianese, Ugo
Caponigro, Vicky
Basilicata, Manuela Giovanna
Salviati, Emanuela
Altucci, Lucia
Campiglia, Pietro
Paolisso, Giuseppe
Barbieri, Michelangela
Benedetti, Rosaria
Sommella, Eduardo
author_facet Scisciola, Lucia
Chianese, Ugo
Caponigro, Vicky
Basilicata, Manuela Giovanna
Salviati, Emanuela
Altucci, Lucia
Campiglia, Pietro
Paolisso, Giuseppe
Barbieri, Michelangela
Benedetti, Rosaria
Sommella, Eduardo
author_sort Scisciola, Lucia
collection PubMed
description BACKGROUND: Sodium–glucose cotransporter 2 (SGLT2) inhibitors constitute the gold standard treatment for type 2 diabetes mellitus (T2DM). Among them, empagliflozin (EMPA) has shown beneficial effects against heart failure. Because cardiovascular diseases (mainly diabetic cardiomyopathy) are the leading cause of death in diabetic patients, the use of EMPA could be, simultaneously, cardioprotective and antidiabetic, reducing the risk of death from cardiovascular causes and decreasing the risk of hospitalization for heart failure in T2DM patients. Interestingly, recent studies have shown that EMPA has positive benefits for people with and without diabetes. This finding broadens the scope of EMPA function beyond glucose regulation alone to include a more intricate metabolic process that is, in part, still unknown. Similarly, this significantly increases the number of people with heart diseases who may be eligible for EMPA treatment. METHODS: This study aimed to clarify the metabolic effect of EMPA on the human myocardial cell model by using orthogonal metabolomics, lipidomics, and proteomics approaches. The untargeted and multivariate analysis mimicked the fasting blood sugar level of T2DM patients (hyperglycemia: HG) and in the average blood sugar range (normal glucose: NG), with and without the addition of EMPA. RESULTS: Results highlighted that EMPA was able to modulate and partially restore the levels of multiple metabolites associated with cellular stress, which were dysregulated in the HG conditions, such as nicotinamide mononucleotide, glucose-6-phosphate, lactic acid, FA 22:6 as well as nucleotide sugars and purine/pyrimidines. Additionally, EMPA regulated the levels of several lipid sub-classes, in particular dihydroceramide and triacylglycerols, which tend to accumulate in HG conditions resulting in lipotoxicity. Finally, EMPA counteracted the dysregulation of endoplasmic reticulum-derived proteins involved in cellular stress management. CONCLUSIONS: These results could suggest an effect of EMPA on different metabolic routes, tending to rescue cardiomyocyte metabolic status towards a healthy phenotype. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04537-1.
format Online
Article
Text
id pubmed-10518098
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105180982023-09-25 Multi-omics analysis reveals attenuation of cellular stress by empagliflozin in high glucose-treated human cardiomyocytes Scisciola, Lucia Chianese, Ugo Caponigro, Vicky Basilicata, Manuela Giovanna Salviati, Emanuela Altucci, Lucia Campiglia, Pietro Paolisso, Giuseppe Barbieri, Michelangela Benedetti, Rosaria Sommella, Eduardo J Transl Med Research BACKGROUND: Sodium–glucose cotransporter 2 (SGLT2) inhibitors constitute the gold standard treatment for type 2 diabetes mellitus (T2DM). Among them, empagliflozin (EMPA) has shown beneficial effects against heart failure. Because cardiovascular diseases (mainly diabetic cardiomyopathy) are the leading cause of death in diabetic patients, the use of EMPA could be, simultaneously, cardioprotective and antidiabetic, reducing the risk of death from cardiovascular causes and decreasing the risk of hospitalization for heart failure in T2DM patients. Interestingly, recent studies have shown that EMPA has positive benefits for people with and without diabetes. This finding broadens the scope of EMPA function beyond glucose regulation alone to include a more intricate metabolic process that is, in part, still unknown. Similarly, this significantly increases the number of people with heart diseases who may be eligible for EMPA treatment. METHODS: This study aimed to clarify the metabolic effect of EMPA on the human myocardial cell model by using orthogonal metabolomics, lipidomics, and proteomics approaches. The untargeted and multivariate analysis mimicked the fasting blood sugar level of T2DM patients (hyperglycemia: HG) and in the average blood sugar range (normal glucose: NG), with and without the addition of EMPA. RESULTS: Results highlighted that EMPA was able to modulate and partially restore the levels of multiple metabolites associated with cellular stress, which were dysregulated in the HG conditions, such as nicotinamide mononucleotide, glucose-6-phosphate, lactic acid, FA 22:6 as well as nucleotide sugars and purine/pyrimidines. Additionally, EMPA regulated the levels of several lipid sub-classes, in particular dihydroceramide and triacylglycerols, which tend to accumulate in HG conditions resulting in lipotoxicity. Finally, EMPA counteracted the dysregulation of endoplasmic reticulum-derived proteins involved in cellular stress management. CONCLUSIONS: These results could suggest an effect of EMPA on different metabolic routes, tending to rescue cardiomyocyte metabolic status towards a healthy phenotype. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04537-1. BioMed Central 2023-09-23 /pmc/articles/PMC10518098/ /pubmed/37742032 http://dx.doi.org/10.1186/s12967-023-04537-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Scisciola, Lucia
Chianese, Ugo
Caponigro, Vicky
Basilicata, Manuela Giovanna
Salviati, Emanuela
Altucci, Lucia
Campiglia, Pietro
Paolisso, Giuseppe
Barbieri, Michelangela
Benedetti, Rosaria
Sommella, Eduardo
Multi-omics analysis reveals attenuation of cellular stress by empagliflozin in high glucose-treated human cardiomyocytes
title Multi-omics analysis reveals attenuation of cellular stress by empagliflozin in high glucose-treated human cardiomyocytes
title_full Multi-omics analysis reveals attenuation of cellular stress by empagliflozin in high glucose-treated human cardiomyocytes
title_fullStr Multi-omics analysis reveals attenuation of cellular stress by empagliflozin in high glucose-treated human cardiomyocytes
title_full_unstemmed Multi-omics analysis reveals attenuation of cellular stress by empagliflozin in high glucose-treated human cardiomyocytes
title_short Multi-omics analysis reveals attenuation of cellular stress by empagliflozin in high glucose-treated human cardiomyocytes
title_sort multi-omics analysis reveals attenuation of cellular stress by empagliflozin in high glucose-treated human cardiomyocytes
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518098/
https://www.ncbi.nlm.nih.gov/pubmed/37742032
http://dx.doi.org/10.1186/s12967-023-04537-1
work_keys_str_mv AT scisciolalucia multiomicsanalysisrevealsattenuationofcellularstressbyempagliflozininhighglucosetreatedhumancardiomyocytes
AT chianeseugo multiomicsanalysisrevealsattenuationofcellularstressbyempagliflozininhighglucosetreatedhumancardiomyocytes
AT caponigrovicky multiomicsanalysisrevealsattenuationofcellularstressbyempagliflozininhighglucosetreatedhumancardiomyocytes
AT basilicatamanuelagiovanna multiomicsanalysisrevealsattenuationofcellularstressbyempagliflozininhighglucosetreatedhumancardiomyocytes
AT salviatiemanuela multiomicsanalysisrevealsattenuationofcellularstressbyempagliflozininhighglucosetreatedhumancardiomyocytes
AT altuccilucia multiomicsanalysisrevealsattenuationofcellularstressbyempagliflozininhighglucosetreatedhumancardiomyocytes
AT campigliapietro multiomicsanalysisrevealsattenuationofcellularstressbyempagliflozininhighglucosetreatedhumancardiomyocytes
AT paolissogiuseppe multiomicsanalysisrevealsattenuationofcellularstressbyempagliflozininhighglucosetreatedhumancardiomyocytes
AT barbierimichelangela multiomicsanalysisrevealsattenuationofcellularstressbyempagliflozininhighglucosetreatedhumancardiomyocytes
AT benedettirosaria multiomicsanalysisrevealsattenuationofcellularstressbyempagliflozininhighglucosetreatedhumancardiomyocytes
AT sommellaeduardo multiomicsanalysisrevealsattenuationofcellularstressbyempagliflozininhighglucosetreatedhumancardiomyocytes